Annual Report 2021

CHAIRMAN’S STATEMENT 7 The United Laboratories International Holdings Limited Annual Report 2021 On behalf of the board of directors (the “Board”) of The United Laboratories International Holdings Limited (the “Company”), I am pleased to present to all shareholders the annual results of the Company and its subsidiaries (the “Group”) for the year ended 31 December 2021 (the “Year”). In 2021, the Omicron variant of COVID-19 cast a shadow on the global economic recovery. However, benefiting from China’s strict epidemic prevention and control measures, social and economic activities have not been significantly affected despite the resurgence of COVID-19 epidemic. At the same time, 2021 is the first year for China to implement the 14th Five-Year Plan. The government continues to take “comprehensively promote the construction of Healthy China” as a major task in the future, and puts forward a series of requirements, such as deepening the reform of the medical and health system, accelerating the establishment of a tiered diagnosis and treatment system, and rolling out reform in national centralised p r ocu r emen t and use o f pha rmaceu t i ca l s and Mr. Tsoi Hoi Shan Chairman consumables. The intensive introduction of policies in the pharmaceutical industry has brought impetus to the long-term development of medical and health undertakings, and pointed out the direction for the future development of the pharmaceutical industry. During the Year, the Group progressed steadily in various productions and operations, and satisfactory progress has been made in the sales of each segment, research and development of new drugs, new product launch and market promotion. In 2021, the Group recorded revenue of approximately RMB9,703.4 million, representing an increase of approximately 10.6% over 2020. EBITDA was approximately RMB1,883.7 million, representing an increase of 12.3% as compared with last year. Profit attributable to owners of the Company was approximately RMB988.1 million, representing an increase of 40.6% as compared with last year. Earnings per share amounted to RMB53.70 cents.